Goldman Sachs: Maintains "Buy" rating on CSPC PHARMA (01093), target price raised to HK$12.83
CSPC PHARMA's finished drug business grew 10% year on year. Retail sales of its core products "NBP" and "Mingfule" continued to expand, driving related business to surge 32% year on year.
Goldman Sachs: Maintains "Buy" rating on CSPC PHARMA (01093), target price raised to HK$12.83
Goldman Sachs released a research report stating that CSPC PHARMA's (01093) third-quarter results were in line with expectations. Despite weak performance in the active pharmaceutical ingredient (API) business, the finished drug business remained solid, growing 10% year-on-year, mainly benefiting from strong performance in the central nervous system (CNS)-related product pipeline. Among them, retail sales of the group's core products "NBP" and "Mongruo" continued to expand, driving related business to grow significantly by 32% year-on-year; while the group's anti-tumor product portfolio remained under pressure, with volume ramp-up expected to take time and yet to become a new growth driver. Goldman Sachs maintains its "Buy" rating on CSPC PHARMA, raising the target price from HK$12.56 to HK$12.83.
The report noted that despite positive momentum in the finished drug business in the second and third quarters, management holds a cautiously optimistic attitude toward future growth, only expecting finished drug sales to achieve positive growth in 2027. In the CNS field, "NBP" is expected to continue supporting sales growth as its price remains unchanged after inclusion in the medical insurance catalog; "Mongruo," after an approximately 9.4% price cut under medical insurance, will offset the impact through expanded sales volume. Management expects multiple new drugs to become important growth engines in 2027, including albumin-bound paclitaxel, GLP-1 drugs, and the EGFR ADC drug SYS6010, which are expected to drive the oncology business back onto a growth trajectory after continued pressure in 2026.
The report also mentioned CSPC PHARMA's layout in new technology platforms, including AI-assisted drug discovery, in vivo CAR-T therapy, mRNA vaccines, siRNA, and long-acting sustained-release systems. Management stated that the CD19-targeting in vivo CAR-T therapy "SYS6055 injection" has demonstrated encouraging efficacy responses in initial dose cohorts, and the group plans to further expand it into autoimmune diseases and refractory solid tumors.
In terms of mRNA therapeutic vaccines, the company is advancing a research project targeting human papillomavirus (HPV), and management noted that the project has shown early efficacy signals in cervical precancerous lesions and HPV-related solid tumors; in addition, SYS6077, a shared-antigen cancer vaccine designed against commonly associated antigens of colorectal cancer (CRC), is expected to initiate Phase I clinical trials in China in the fourth quarter of 2026.
Related Articles

MS CONCEPT (08447) announces interim results, with a net loss of HK$1.521 million.

Zijin Mining Group (02899) plans to repurchase RMB2 billion to RMB3 billion of its A-shares.

US Stock Market Move | NVIDIA Corporation (NVDA.US) rose 4%; institutions believe the stock price has already priced in the risk of leadership changes.
MS CONCEPT (08447) announces interim results, with a net loss of HK$1.521 million.

Zijin Mining Group (02899) plans to repurchase RMB2 billion to RMB3 billion of its A-shares.

US Stock Market Move | NVIDIA Corporation (NVDA.US) rose 4%; institutions believe the stock price has already priced in the risk of leadership changes.






